denileukin diftitox (ontak) Report issue

Biologics Recombinant protein Orphan Drug FDA Approved FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Denileukin diftitox was an antineoplastic agent, an engineered protein combining interleukin-2 and diphtheria toxin. Denileukin diftitox could bind to interleukin-2 receptors and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some leukemias and lymphomas, malignant cells express these receptors, so denileukin diftitox can target these.   Wikipedia

More Chemistry
dab(389)-il-2 | dab(389)il-2 | dab389 il2 | dab389-il-2 | dab(389)-interleukin 2 | denileukin diftitox | diphtheria toxin precursor | dt | ly-335348 | nad(+--diphthamide adp- ribosyltransferase) | ontak

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue